Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay

Published:2022 Issue:6 Volume:25 Page:473
ISSN:1738-6756
Container-title:Journal of Breast Cancer
language:en
Short-container-title:J Breast Cancer

Author:

Lee Jun-Hee¹^ORCID,Ryu Jai Min¹^ORCID,Ahn Jee Hyun²^ORCID,Cho Soo Youn³^ORCID,Lee Se Kyung¹^ORCID,Yu Jonghan¹^ORCID,Chae Byung Joo¹^ORCID,Nam Seok Jin¹^ORCID,Han Jinil⁴^ORCID,Lee Jeong Eon¹^ORCID,Kim Seok Won¹^ORCID

Affiliation:

1. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

2. Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.

3. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

4. Gencurix, Inc., Seoul, Korea.

Funder

Korea Breast Cancer Foundation

National Research Foundation of Korea

Research Institute for Future Medicine, Samsung Medical Center

Publisher

Korean Breast Cancer Society

Subject

Cancer Research,Oncology

Link

https://ejbc.kr/pdf/10.4048/jbc.2022.25.e49

Reference32 articles.

1. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer

2. Translating neoadjuvant therapy into survival benefits: one size does not fit all

3. Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies

4. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

5. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of treatment responses among subgroups of breast cancer patients receiving neoadjuvant chemotherapy;Journal of Cancer Research and Therapeutics;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3